The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESMO 2019 | Sym015: MET antibody mixture for advanced solid tumors

Name: Sym015: MET antibody mixture for advanced solid tumors
Uploaded: 2019-09-28T00:00:00Z
Duration: 59 s
Description: Ross Camidge, MD, PhD, University of Colorado, Denver, CO, discusses the phase 1a/2a trial of Sym015, a MET antibody mixture, in patients with advanced solid tumors. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Ross Camidge • 28 Sep 2019

ESMO 2019

General Lung Cancer Antibodies Sym015

Ross Camidge, MD, PhD, University of Colorado, Denver, CO, discusses the phase 1a/2a trial of Sym015, a MET antibody mixture, in patients with advanced solid tumors. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.